Heart sounds are the acoustic vibrations produced during the systole and diastole of the cardiac cycle. The art of evaluating the acoustic properties of heart sounds is known as heart auscultation. Heart auscultation has long been the most common technique for assessing the cardiac function of a patient. Conventional medical practice uses a mechanical stethoscope for auscultation. Often, the practitioners would need to rely on their hearing ability and their subjective judgement on the interpretation of the sounds. With the introduction of electronic stethoscopes, people are now hoping to measure and analyze heart sounds in a more objective manner. The rapid development in microchip technology in the past decade has resulted in electronic stethoscopes that are portable, robust to noise, and convenient to use. The future trend of electronic stethoscope would be a multifunctional auscultatory device with graphical display, wireless data transmission, real‐time signal processing for noise removal, selectable frequency response, etc. The newly developed electronic stethoscopes allow heart sounds to be digitally recorded and downloaded to a computer for analysis. Many of the computer‐based heart sound analysis techniques adopted by researchers, for example, wavelet transform and neural network, have already provided new insight into the diagnostic value of heart sound. The exploration of further techniques in the coming years would hopefully help to realize the full potential of heart sound auscultation as a tool the early detection of heart diseases.

In January 1998, a 14-month-old girl presented with fever and dyspnoea. Plain chest radiograph showed opacification of the right hemithorax that corresponded to a multicystic mass on computed tomography. Thoracotomy was performed and a 11-cm × 9.5-cm × 5-cm mixed cystic-solid mass excised. Together with histological findings, type II pleuropulmonary blastoma (PPB) was diagnosed. The patient was treated with adjuvant chemotherapy according to the Intergroup Rhabdomyosarcoma Study-IV regimen but developed ifosfamideinduced renal tubulopathy. At the time of writing, the patient remains in remission (age 23 years). Sanger sequencing revealed no DICER1 mutation in the patient's peripheral blood DNA.

No abstract